Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Industry Reps Call for Early Discussions on Inclusion of Vaccines in Public Vaccination Programs: Hearings
March 3, 2017
- MHLW Advisory Panel Backs Shionogi’s Pediatric ADHD Drug
March 3, 2017
- New CEFP Working Group on Assessment and Analysis Launches Discussions
March 2, 2017
- Non-Partisan Lawmaker Group on Healthcare Boots Up, Plans Fortnightly Hearings
March 2, 2017
- MHLW to Tap NCCHD Database to Improve Pediatric Drug Use Environment
March 2, 2017
- Conduct Surprise Inspections on Wholesalers/Pharmacies by March-End, MHLW Asks Pref. Authorities
March 2, 2017
- MHLW OKs 53 NMEs in 2016
March 2, 2017
- 7 Products Including iPS Cell-Derived Product Receive Sakigake Review Status in the Second Round of Designations
March 2, 2017
- MHLW Summons NHK, MSD over Misleading TV Program
February 28, 2017
- Pros and Cons for Setting Up “International Center for Regenerative Medicine”: LDP, Komeito Lawmakers
February 27, 2017
- AMED to Deploy “Site Coordinators” to Expedite Drug Discovery
February 24, 2017
- Is “No Gx Substitution” Column in Scripts Still Necessary? Asks Chuikyo Payer Rep
February 23, 2017
- Foreign Price Adjustment Doesn’t Make Much Sense for Drugs with Similar Meds in Japan: Industry
February 23, 2017
- Overhaul Rules to Pick Comparator Meds in Similar Drug Pricing Method: Chuikyo Rep
February 23, 2017
- Council Drafts Scheme to Provide Unapproved Drugs in Response to Infectious Disease Outbreaks in Developing Countries
February 23, 2017
- Use of Generic Drugs Increases, Lingering Concerns Over Quality: Survey
February 23, 2017
- CEFP Working Group to Go Full Throttle on Policy Guidelines Debate in March
February 22, 2017
- New Formats for Package Inserts to Be Announced in April, Enforced from FY2019 with Transition Period: MHLW
February 21, 2017
- MHLW to Strike Balance between Pricing Reform and Generic Promotion: Official
February 20, 2017
- MHLW Advisory Committee to Discuss Ninlaro on March 3
February 20, 2017
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…